1Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Circulation, 2001, 103:163-182.
2Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest, 1998,114(5 Suppl):5795-5895.
3Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. A multicenter, prospective, randomized trial. Stroke, 2000, 31:817-821.
4Levy S, Brelthardt G, Campbell RW, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J, 1998, 19:1294-1320.
5Antiplatelet Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J, 2000, 324:71-86.
6Hsievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation, 2002, 105:1887-1891.
7Ezekowita MD, Levine JA. Preventing stoke in patients with atrial fibrillation. JAMA, 1999, 281: 1830-1835.
8Ulf G. Eriksson,Ulf Bredberg,Kristina Gislén,Linda C. Johansson,Lars Frison,Martin Ahnoff,David Gustafsson. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects[J] 2003,European Journal of Clinical Pharmacology(1):35～43
